EHA Library - The official digital education library of European Hematology Association (EHA)

EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER
Author(s): ,
M. Macro
Affiliations:
CHU Caen,Caen,France;CHU Caen,Caen,Frankreich;CHU Caen,Caen,Francia;CHU Caen,Caen,France;CHU Caen,Caen,Francia;CHU Caen,Caen,Frankrijk;CHU Caen,Caen,França;CHU Caen,Caen,Франция ;CHU Caen,Caen,Frankrike
,
O Decaux
Affiliations:
C.H.U de Rennes,Rennes ,France;C.H.U de Rennes,Rennes ,Frankreich;C.H.U de Rennes,Rennes ,Francia;C.H.U de Rennes,Rennes ,France;C.H.U de Rennes,Rennes ,Francia;C.H.U de Rennes,Rennes ,Frankrijk;C.H.U de Rennes,Rennes ,França;C.H.U de Rennes,Rennes ,Франция ;C.H.U de Rennes,Rennes ,Frankrike
,
A Perrot
Affiliations:
Institut Universitaire du Cancer Toulouse Oncopole,Toulouse,France;Institut Universitaire du Cancer Toulouse Oncopole,Toulouse,Frankreich;Institut Universitaire du Cancer Toulouse Oncopole,Toulouse,Francia;Institut Universitaire du Cancer Toulouse Oncopole,Toulouse,France;Institut Universitaire du Cancer Toulouse Oncopole,Toulouse,Francia;Institut Universitaire du Cancer Toulouse Oncopole,Toulouse
,
B Royer
Affiliations:
hôpital st louis, aphp,Paris,France;hôpital st louis, aphp,Paris,Frankreich;hôpital st louis, aphp,Paris,Francia;hôpital st louis, aphp,Paris,France;hôpital st louis, aphp,Paris,Francia;hôpital st louis, aphp,Paris,Frankrijk;hôpital st louis, aphp,Paris,França;hôpital st louis, aphp,Paris,Франция ;hôpital st louis, aphp,Paris,Frankrike
,
M.L. Chretien
Affiliations:
CHU Dijon,Dijon,France;CHU Dijon,Dijon,Frankreich;CHU Dijon,Dijon,Francia;CHU Dijon,Dijon,France;CHU Dijon,Dijon,Francia;CHU Dijon,Dijon,Frankrijk;CHU Dijon,Dijon,França;CHU Dijon,Dijon,Франция ;CHU Dijon,Dijon,Frankrike
,
K Belhadj
Affiliations:
Hôpital Henri Mondor,Creteil,France;Hôpital Henri Mondor,Creteil,Frankreich;Hôpital Henri Mondor,Creteil,Francia;Hôpital Henri Mondor,Creteil,France;Hôpital Henri Mondor,Creteil,Francia;Hôpital Henri Mondor,Creteil,Frankrijk;Hôpital Henri Mondor,Creteil,França;Hôpital Henri Mondor,Creteil,Франция ;Hôpital Henri Mondor,Creteil,Frankrike
,
M Mohty
Affiliations:
Hôpital Saint-Antoine,paris ,France;Hôpital Saint-Antoine,paris ,Frankreich;Hôpital Saint-Antoine,paris ,Francia;Hôpital Saint-Antoine,paris ,France;Hôpital Saint-Antoine,paris ,Francia;Hôpital Saint-Antoine,paris ,Frankrijk;Hôpital Saint-Antoine,paris ,França;Hôpital Saint-Antoine,paris ,Франция ;Hôpital Saint-Antoine,paris ,Frankrike
,
L Frenzel
Affiliations:
Hôpital Necker,paris,France;Hôpital Necker,paris,Frankreich;Hôpital Necker,paris,Francia;Hôpital Necker,paris,France;Hôpital Necker,paris,Francia;Hôpital Necker,paris,Frankrijk;Hôpital Necker,paris,França;Hôpital Necker,paris,Франция ;Hôpital Necker,paris,Frankrike
,
X Leleu
Affiliations:
CHU de Poitiers,Potiers ,France;CHU de Poitiers,Potiers ,Frankreich;CHU de Poitiers,Potiers ,Francia;CHU de Poitiers,Potiers ,France;CHU de Poitiers,Potiers ,Francia;CHU de Poitiers,Potiers ,Frankrijk;CHU de Poitiers,Potiers ,França;CHU de Poitiers,Potiers ,Франция ;CHU de Poitiers,Potiers ,Frankrike
,
M Dib
Affiliations:
CHU Angers,Angers,France;CHU Angers,Angers,Frankreich;CHU Angers,Angers,Francia;CHU Angers,Angers,France;CHU Angers,Angers,Francia;CHU Angers,Angers,Frankrijk;CHU Angers,Angers,França;CHU Angers,Angers,Франция ;CHU Angers,Angers,Frankrike
,
O Allangba
Affiliations:
C.H. Yves le Foll,ST Brieuc,France;C.H. Yves le Foll,ST Brieuc,Frankreich;C.H. Yves le Foll,ST Brieuc,Francia;C.H. Yves le Foll,ST Brieuc,France;C.H. Yves le Foll,ST Brieuc,Francia;C.H. Yves le Foll,ST Brieuc,Frankrijk;C.H. Yves le Foll,ST Brieuc,França;C.H. Yves le Foll,ST Brieuc,Франция ;C.H. Yves le Foll,ST Brieuc,Frankrike
,
P Zunic
Affiliations:
CHU Réunion Sud,St Pierre,France;CHU Réunion Sud,St Pierre,Frankreich;CHU Réunion Sud,St Pierre,Francia;CHU Réunion Sud,St Pierre,France;CHU Réunion Sud,St Pierre,Francia;CHU Réunion Sud,St Pierre,Frankrijk;CHU Réunion Sud,St Pierre,França;CHU Réunion Sud,St Pierre,Франция ;CHU Réunion Sud,St Pierre,Frankrike
,
I Botoc
Affiliations:
CH Saint-Malo,Saint Malo,France;CH Saint-Malo,Saint Malo,Frankreich;CH Saint-Malo,Saint Malo,Francia;CH Saint-Malo,Saint Malo,France;CH Saint-Malo,Saint Malo,Francia;CH Saint-Malo,Saint Malo,Frankrijk;CH Saint-Malo,Saint Malo,França;CH Saint-Malo,Saint Malo,Франция ;CH Saint-Malo,Saint Malo,Frankrike
,
J.Y. Malfuson
Affiliations:
Hôpital d'Instruction des Armées Percy,Clamart,France;Hôpital d'Instruction des Armées Percy,Clamart,Frankreich;Hôpital d'Instruction des Armées Percy,Clamart,Francia;Hôpital d'Instruction des Armées Percy,Clamart,France;Hôpital d'Instruction des Armées Percy,Clamart,Francia;Hôpital d'Instruction des Armées Percy,Clamart,Frankrijk;Hôpital d'Instruction des Armées Percy,Clamart,França;Hôpital d'Ins
,
P Moreau
Affiliations:
CHU nantes,Nantes ,France;CHU nantes,Nantes ,Frankreich;CHU nantes,Nantes ,Francia;CHU nantes,Nantes ,France;CHU nantes,Nantes ,Francia;CHU nantes,Nantes ,Frankrijk;CHU nantes,Nantes ,França;CHU nantes,Nantes ,Франция ;CHU nantes,Nantes ,Frankrike
,
R. Garlantazec
Affiliations:
CHU Rennes ,Rennes,France;CHU Rennes ,Rennes,Frankreich;CHU Rennes ,Rennes,Francia;CHU Rennes ,Rennes,France;CHU Rennes ,Rennes,Francia;CHU Rennes ,Rennes,Frankrijk;CHU Rennes ,Rennes,França;CHU Rennes ,Rennes,Франция ;CHU Rennes ,Rennes,Frankrike
,
N Texier
Affiliations:
kappa santé,paris,France;kappa santé,paris,Frankreich;kappa santé,paris,Francia;kappa santé,paris,France;kappa santé,paris,Francia;kappa santé,paris,Frankrijk;kappa santé,paris,França;kappa santé,paris,Франция ;kappa santé,paris,Frankrike
,
R. Germain
Affiliations:
Kappa Santé ,Paris ,France;Kappa Santé ,Paris ,Frankreich;Kappa Santé ,Paris ,Francia;Kappa Santé ,Paris ,France;Kappa Santé ,Paris ,Francia;Kappa Santé ,Paris ,Frankrijk;Kappa Santé ,Paris ,França;Kappa Santé ,Paris ,Франция ;Kappa Santé ,Paris ,Frankrike
,
C. Deal
Affiliations:
IFM,Paris,France;IFM,Paris,Frankreich;IFM,Paris,Francia;IFM,Paris,France;IFM,Paris,Francia;IFM,Paris,Frankrijk;IFM,Paris,França;IFM,Paris,Франция ;IFM,Paris,Frankrike
C. Hulin
Affiliations:
CHU Bordeaux,Bordeaux,France;CHU Bordeaux,Bordeaux,Frankreich;CHU Bordeaux,Bordeaux,Francia;CHU Bordeaux,Bordeaux,France;CHU Bordeaux,Bordeaux,Francia;CHU Bordeaux,Bordeaux,Frankrijk;CHU Bordeaux,Bordeaux,França;CHU Bordeaux,Bordeaux,Франция ;CHU Bordeaux,Bordeaux,Frankrike
(Abstract release date: 05/12/22) EHA Library. Macro M. 06/10/22; 357816; P956
Margaret Macro
Margaret Macro
Contributions
Abstract
Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until Monday, August 15, 2022 on the Congress platform.

Abstract: P956

Type: Poster presentation

Session title: Myeloma and other monoclonal gammopathies - Clinical

Background

Multiple myeloma (MM) patients aged 80 years and older are a population more prone to comorbidities, frailty, cognitive impairment or physical decline and require appropriate management of their myeloma. They are often underrepresented in pivotal clinical trials, with little data available on their management. The EMMY study is a large-scale epidemiological study to assess the epidemiology and real-life management of MM and can focus on the use and real-life efficacy of treatments for newly diagnosed or relapsed/ refractory elderly MM patients.

Aims

To describe the management of MM in newly diagnosed or relapsed patients aged 80 years and over and to assess the real-life effectiveness of the treatments received.

Methods

EMMY is a descriptive, multicenter, national, non-interventional study conducted in 72 IFM (Intergroupe Francophone du Myélome, sponsor) centers in France. Any patient initiating treatment for MM over a 3-month observation period, from October to December, is included, since 2017. It is a dynamic cohort with the inclusion of approximately 900 patients each year: 2765 patients included at the end of 2019 of which 561 were aged 80 and over (20.3%). Data are updated annually from hospital records up to 2020 at the time of the analysis.

Four cohorts of patients aged 80 years and older were analysed according to the line of treatment initiated during their follow-up: L1, L2, L3 or L4+. Median time to next treatment (mTNT), median progression-free survival (mPFS) and median overall survival (mOS) were assessed in months(m).

Results

Patients ≥80 years initiated 19.8% of L1s (237/1199) 22.7% (232/1022) of L2s, 22.2% (167/751) of L3s and 18.7% (288/1540) of L4+. They are 7.5% patients ≥85 years old to initiate L1, 8.7% L2, 7.4% L3 and 5.1% L4+. When the line is started, an ECOG ≥2 is reported for 39.4% of L1, 27.7% of L2, 35.1% of L3 and 38.5% of L4 patients and comorbidities recorded in 45.1% of L1, 39.6% of L2, 35.4% of L3 and 38.6% of L4+. In L1, the ISS is level I, II, III for 20.2%, 27.4% and 52.4% of patients.

In L1, over the 2017-2020 study period, patients received treatment with PI (58.6%), IMID (32.1%), PI/IMID (4.2%), anti-CD38 (1.3%) or other molecules (3.8%). In L2, they received PI (22.8%), IMID (48.7%), PI/IMID (11.7%), anti-CD38 (14.2%) or other (2.6%), in L3 PI (12.6%), IMID (38, 9%), PI/IMID (9.6%), anti-CD38 (29.3%) or other (9.6%) and in L4+ a PI (23.3%), IMID (20.1%), PI/IMID (5.6%), anti-CD38 (29.2%) or other (21.9%). More than half received a double combination in L1 (50.2%), L2 (59.9%), L3 (54.4%) and L4+ (53.8%).

Regarding efficacy, mTNT is 20.3m [15.2; 24.6] in L1, 14.7m [12.3; 20.4] in L2, 10.8m [9; 13.5] in L3 and 8.2m [6.5; 11.2] in L4+. The mPFS is 19.3m [15.1; 23.2] in L1, 12.6m [10.1; 17.5] in L2, 8.9m [10.1; 17.5] in L3 and 5.9m [4.5;7.4] in L4+. The mOS is not reached in L1 (rate at 30m: 76.7% [70; 83.3]) and L2 (rate at 30m: 58.1% [48.1; 68]; it is 25.7m [17.1; NE] in L3 and 18.3m [13.4; 22.4] in L4+.

Conclusion

Patients ≥80 years of age account for more than 20% of de novo and relapsed myeloma patients treated in EMMY. Double combinations are used in half of the situations. Over the study period, PI-based treatments were preferred in L1, IMID-based in L2 and antiCD38 for 30% of patients in L3 and L4+. The benefits in terms of survival are real and this specific population is likely to increase significantly in the near future, requiring human and logistical resources.

Keyword(s):

Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until Monday, August 15, 2022 on the Congress platform.

Abstract: P956

Type: Poster presentation

Session title: Myeloma and other monoclonal gammopathies - Clinical

Background

Multiple myeloma (MM) patients aged 80 years and older are a population more prone to comorbidities, frailty, cognitive impairment or physical decline and require appropriate management of their myeloma. They are often underrepresented in pivotal clinical trials, with little data available on their management. The EMMY study is a large-scale epidemiological study to assess the epidemiology and real-life management of MM and can focus on the use and real-life efficacy of treatments for newly diagnosed or relapsed/ refractory elderly MM patients.

Aims

To describe the management of MM in newly diagnosed or relapsed patients aged 80 years and over and to assess the real-life effectiveness of the treatments received.

Methods

EMMY is a descriptive, multicenter, national, non-interventional study conducted in 72 IFM (Intergroupe Francophone du Myélome, sponsor) centers in France. Any patient initiating treatment for MM over a 3-month observation period, from October to December, is included, since 2017. It is a dynamic cohort with the inclusion of approximately 900 patients each year: 2765 patients included at the end of 2019 of which 561 were aged 80 and over (20.3%). Data are updated annually from hospital records up to 2020 at the time of the analysis.

Four cohorts of patients aged 80 years and older were analysed according to the line of treatment initiated during their follow-up: L1, L2, L3 or L4+. Median time to next treatment (mTNT), median progression-free survival (mPFS) and median overall survival (mOS) were assessed in months(m).

Results

Patients ≥80 years initiated 19.8% of L1s (237/1199) 22.7% (232/1022) of L2s, 22.2% (167/751) of L3s and 18.7% (288/1540) of L4+. They are 7.5% patients ≥85 years old to initiate L1, 8.7% L2, 7.4% L3 and 5.1% L4+. When the line is started, an ECOG ≥2 is reported for 39.4% of L1, 27.7% of L2, 35.1% of L3 and 38.5% of L4 patients and comorbidities recorded in 45.1% of L1, 39.6% of L2, 35.4% of L3 and 38.6% of L4+. In L1, the ISS is level I, II, III for 20.2%, 27.4% and 52.4% of patients.

In L1, over the 2017-2020 study period, patients received treatment with PI (58.6%), IMID (32.1%), PI/IMID (4.2%), anti-CD38 (1.3%) or other molecules (3.8%). In L2, they received PI (22.8%), IMID (48.7%), PI/IMID (11.7%), anti-CD38 (14.2%) or other (2.6%), in L3 PI (12.6%), IMID (38, 9%), PI/IMID (9.6%), anti-CD38 (29.3%) or other (9.6%) and in L4+ a PI (23.3%), IMID (20.1%), PI/IMID (5.6%), anti-CD38 (29.2%) or other (21.9%). More than half received a double combination in L1 (50.2%), L2 (59.9%), L3 (54.4%) and L4+ (53.8%).

Regarding efficacy, mTNT is 20.3m [15.2; 24.6] in L1, 14.7m [12.3; 20.4] in L2, 10.8m [9; 13.5] in L3 and 8.2m [6.5; 11.2] in L4+. The mPFS is 19.3m [15.1; 23.2] in L1, 12.6m [10.1; 17.5] in L2, 8.9m [10.1; 17.5] in L3 and 5.9m [4.5;7.4] in L4+. The mOS is not reached in L1 (rate at 30m: 76.7% [70; 83.3]) and L2 (rate at 30m: 58.1% [48.1; 68]; it is 25.7m [17.1; NE] in L3 and 18.3m [13.4; 22.4] in L4+.

Conclusion

Patients ≥80 years of age account for more than 20% of de novo and relapsed myeloma patients treated in EMMY. Double combinations are used in half of the situations. Over the study period, PI-based treatments were preferred in L1, IMID-based in L2 and antiCD38 for 30% of patients in L3 and L4+. The benefits in terms of survival are real and this specific population is likely to increase significantly in the near future, requiring human and logistical resources.

Keyword(s):

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies